Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We examined the concept of a novel prodrug strategy in which anticancer drug can be locally released by visible/near IR light, taking advantage of the photodynamic process and photo-unclick chemistry. Our most recently formulated prodrug of combretastatin A-4, Pc-(L-CA4)2, showed multifunctionality for fluorescence imaging, light-activated drug release, and the combined effects of PDT and local chemotherapy. In this formulation, L is a singlet oxygen cleavable linker. Here, we advanced this multifunctional prodrug by adding a tumor-targeting group, folic acid (FA). We designed and prepared four FA-conjugated prodrugs 1-4 (CA4-L-Pc-PEGn-FA: n = 0, 2, 18, ∼45) and one non-FA-conjugated prodrug 5 (CA4-L-Pc-PEG18-boc). Prodrugs 3 and 4 had a longer PEG spacer and showed higher hydrophilicity, enhanced uptake to colon 26 cells via FR-mediated mechanisms, and more specific localization to SC colon 26 tumors in Balb/c mice than prodrugs 1 and 2. Prodrug 4 also showed higher and more specific uptake to tumors, resulting in selective tumor damage and more effective antitumor efficacy than non-FA-conjugated prodrug 5. FR-mediated targeting seemed to be an effective strategy to spare normal tissues surrounding tumors in the illuminated area during treatment with this prodrug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Andresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580
Light‐sensitive Intelligent Drug Delivery Systems†
Alvarez‐Lorenzo, C., Bromberg, L., & Concheiro, A. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2008.00530.x · Cited by 519
Cited by
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy
Gao, M., Yu, F., Lv, C., Choo, J., & Chen, L. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00908e · Cited by 827
Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials
Weinstain, R., Slanina, T., Kand, D., & Klán, P. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00663 · Cited by 642
Advances in targeting the folate receptor in the treatment/imaging of cancers
Fernández, M., Javaid, F., & Chudasama, V. (2018) · Chemical Science · doi:10.1039/c7sc04004k · Cited by 539
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Small conjugate-based theranostic agents: an encouraging approach for cancer therapy
Kumar, R., Shin, W. S., Sunwoo, K., Kim, W. Y., Koo, S., Bhuniya, S., & Kim, J. S. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00224a · Cited by 381
Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics
Lee, M. H., Sharma, A., Chang, M. J., Lee, J., Son, S., Sessler, J. L., Kang, C., & Kim, J. S. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00557a · Cited by 317
ROS‐responsive drug delivery systems
Liang, J., & Liu, B. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10014 · Cited by 274
Metadata
- Authors
- Nkepang, G., Bio, M., Rajaputra, P., Awuah, S. G., & You, Y.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-11-21
- Volume
- 25
- Issue
- 12
- Pages
- 2175-2188
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W1967290375
- Cited by
- 73
- References
- 2
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.